Biotron finds strong antiviral activity as SedRx moves toward European trial planning

BIT-HBV001 posts strong cell-based antiviral results

Biotron Limited (ASX:BIT) has reported encouraging laboratory results for its lead antiviral candidate BIT-HBV001, including a 99.7% reduction in HBV-DNA and a 98.1% reduction in HBsAg in HBV/HDV co-infected cells. The studies were conducted at The Scripps Research Institute in San Diego and compared BIT-HBV001 directly with Myrcludex B, marketed as Hepcludex for chronic HDV infection.

The comparison was not uniformly in Biotron’s favour: Myrcludex B produced the larger reduction in HDAg, at 94.8% versus 81.0% for BIT-HBV001. In a separate combination study, however, the two treatments showed significant antiviral synergy across three HBV and HDV replication endpoints under four statistical models. The findings support further evaluation of BIT-HBV001 in combination treatment strategies, but they remain cell-based results rather than evidence of clinical efficacy.

SedRx pathway remains tied to pivotal trial advice

Biotron continued preparing an updated submission to the European Medicines Agency to clarify the regulatory pathway and pivotal clinical trial or trials required for SedRx, its next-generation alfaxalone general anaesthetic. The work follows earlier EMA feedback that ruled out a Hybrid Marketing Authorisation pathway and shifted attention towards pivotal clinical development.

The company is also procuring drug product, developing assays and designing animal studies for SedRx in an additional neurological indication. Neither the EMA development pathway nor the pivotal trial design has been finalised in the quarterly report, leaving regulatory advice as the immediate milestone for the anaesthetic program.

Cash runway and leadership transition add pressure

Biotron ended September with A$1.060 million in cash and used A$494,000 in operating activities during the quarter, including A$82,000 on research and development. On that quarter’s operating cash outflow, the company estimated 2.15 quarters of funding. It subsequently received an additional A$208,463 refundable amount from an amended Australian Taxation Office assessment, lifting total tax offset refunds recognised for the year to about A$2.022 million.

The quarter also brought a management change. Michelle Miller stepped down as managing director and chief executive officer on 14 September after 24 years with the company. Glenn Gilbert, whose appointment was covered in Glenn Gilbert CEO appointment, is due to become CEO and executive director on 18 January 2027, while Michael Thurn has joined the board as a non-executive director with immediate effect.

Regulatory and partnering decisions ahead

Biotron’s near-term agenda now rests on two different kinds of validation: regulatory clarity for SedRx and a development or partnering strategy for BIT-HBV001. The antiviral data provide a stronger laboratory case for combination research, while the limited cash runway means the pace and cost of moving either program beyond its current stage will remain important.